Application of total flavonoids aglycon extract of baical skullcap root in preparation of medicament for preventing and treating pulmonary fibrosis

A technology of total flavonoid aglycone and pulmonary fibrosis, applied in the field of medicine, can solve the problems of pulmonary fibrosis that have not yet been seen, and achieve the effect of reducing fibroblast proliferation, reducing lung coefficient, and reducing the degree of pulmonary fibrosis

Inactive Publication Date: 2010-06-16
苏州中药研究所有限公司
View PDF1 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

"(Zhang Yongyi et al.: A preparation method and application of total flavonoid aglycone extract of Scutellaria baicalensis, application number: 200810204811.8, June 17,

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of total flavonoids aglycon extract of baical skullcap root in preparation of medicament for preventing and treating pulmonary fibrosis
  • Application of total flavonoids aglycon extract of baical skullcap root in preparation of medicament for preventing and treating pulmonary fibrosis
  • Application of total flavonoids aglycon extract of baical skullcap root in preparation of medicament for preventing and treating pulmonary fibrosis

Examples

Experimental program
Comparison scheme
Effect test

Example Embodiment

[0036] Example 1

[0037] 1.1 Experimental purpose: To observe the effect of the total flavonoid aglycone extract of Scutellaria baicalensis Georgi on the body weight and lung coefficient of BLM-induced pulmonary fibrosis mice

[0038] 1.2 Experimental materials

[0039] Experimental animals: 90 Kunming mice, both ♀ and ♂, weighing 18-22 grams, clean grade, provided by the Animal Experiment Center of Soochow University. Laboratory animal license number: SYXK (Su) 2007-0035. Laboratory animal production license number: SCXK (Su) 2007-0007.

[0040] Experimental drug: Scutellaria baicalensis total flavonoid aglycone extract (total flavonoid aglycone content ≥50%), batch number: 090424, brown powder, extracted by the plant chemical laboratory of our institute according to existing technology, stored in a refrigerator at 4°C, and used before use 5% sodium carboxymethyl cellulose (CMC-Na) dissolved; bleomycin A5 (BLM A5), white freeze-dried powder, 15mg / piece, manufactured by Nippon Kaya...

Example Embodiment

[0055] Example 2

[0056] 2.1 Experimental purpose: To observe the effect of the total flavonoid aglycone extract of Scutellaria baicalensis Georgi on the serum SOD activity, MDA content and the ability to inhibit ·OH in mice with BLM-induced pulmonary fibrosis

[0057] 1.2 Experimental materials

[0058] Experimental animals: 90 Kunming mice, both ♀ and ♂, weighing 18-22 grams, clean grade, provided by the Animal Experiment Center of Soochow University. Laboratory animal license number: SYXK (Su) 2007-0035. Laboratory animal production license number: SCXK (Su) 2007-0007.

[0059] Experimental drug: Scutellaria baicalensis total flavonoid aglycone extract (total flavonoid aglycone content ≥50%), batch number: 090424, brown powder, extracted by the plant chemical laboratory of our institute according to existing technology, stored in a refrigerator at 4°C, and used before use 5% sodium carboxymethyl cellulose (CMC-Na) dissolved; bleomycin A5 (BLM A5), white freeze-dried powder, 15mg...

Example Embodiment

[0076] Example three

[0077] 3.1 Experimental purpose: To observe the effects of the total flavonoid aglycone extract of Scutellaria baicalensis Georgi on SOD activity, MDA content and T-AOC in lung tissue of BLM-induced pulmonary fibrosis mice

[0078] 3.2 Experimental materials

[0079] Experimental animals: 90 Kunming mice, both ♀ and ♂, weighing 18-22 grams, clean grade, provided by the Animal Experiment Center of Soochow University. Laboratory animal license number: SYXK (Su) 2007-0035. Laboratory animal production license number: SCXK (Su) 2007-0007.

[0080] Experimental drug: Scutellaria baicalensis total flavonoid aglycone extract (total flavonoid aglycone content ≥50%), batch number: 090424, brown powder, extracted by the plant chemical laboratory of our institute according to existing technology, stored in a refrigerator at 4°C, and used before use 5% sodium carboxymethyl cellulose (CMC-Na) dissolved; bleomycin A5 (BLM A5), white freeze-dried powder, 15mg / piece, manufact...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses application of a total flavonoids aglycon extract of baical skullcap root in the preparation of a medicament for preventing and treating pulmonary fibrosis. The invention adopts a technical scheme that: by internally instilling bleomycin AS (BLM A5) in the weasand, a mouse pulmonary fibrosis animal model is copied; the total flavonoids aglycon extract (the content of total flavonoids aglycon is more than or equal to 50 percent) of the baical skullcap root is selected as the treatment medicament for the first time; the interference effect of the total flavonoids aglycon extract of the baical skullcap root on biochemical indexes associated with the serum and the lung tissue of the pulmonary fibrosis animal model and the influence of the total flavonoids aglycon extract of the baical skullcap root on the pathomorphism of the lung tissue are observed to provide an experiment evidence for the treatment of pulmonary fibrosis diseases by the total flavonoids aglycon extract of the baical skullcap root. The medicament is a medicament prepared by combining a therapeutically effective amount of the total flavonoids aglycon extract of the baical skullcap root and a pharmaceutically acceptable vector.

Description

technical field [0001] The present invention relates to the application of an extract of the effective part of a traditional Chinese medicine in the preparation of a drug for preventing and treating pulmonary fibrosis, in particular to the application of the effective part of the traditional Chinese medicine Scutellaria baicalensis, the total flavonoid aglycone extract of Scutellaria baicalensis, in the preparation of a drug for preventing and treating pulmonary fibrosis , belonging to the field of medical technology. Background technique [0002] Pulmonary (interstitial) fibrosis (Pulmonary fibrosis, PF), also known as interstitial lung disease (Interstitiallung disease, ILD), is a common outcome of acute and chronic lung diseases caused by various causes. The etiology is complex, and it is now believed that it may be related to genetic susceptibility, viral infection, abnormal immune function, environmental pollution, drugs and chemicals, and radiation. About 50% of ILD i...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K36/539A61P11/00
Inventor 顾振纶蒋小岗郅玲然郭次仪周忠继
Owner 苏州中药研究所有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap